Comparative Pharmacology
Head-to-head clinical analysis: NYSTATIN TRIAMCINOLONE ACETONIDE versus TRIESENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYSTATIN TRIAMCINOLONE ACETONIDE versus TRIESENCE.
NYSTATIN-TRIAMCINOLONE ACETONIDE vs TRIESENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nystatin is a polyene antifungal that binds to ergosterol in the fungal cell membrane, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
Apply topically to affected area twice daily for 2-4 weeks.
1 to 4 mg (0.025 to 0.1 mL of 40 mg/mL suspension) intravitreal injection once.
None Documented
None Documented
Nystatin: negligible systemic half-life due to lack of absorption. Triamcinolone acetonide: terminal half-life ~2-5 hours (mean ~3.5 h) after intravascular administration; prolonged in hepatic impairment.
Approximately 3.3 hours for triamcinolone acetonide; with intravitreal administration, detectable levels persist for weeks to months.
Nystatin: negligible systemic absorption; excreted unchanged in feces (~100%). Triamcinolone acetonide: metabolized hepatically; renal excretion of metabolites (~40%) and unchanged drug (<5%); fecal excretion (~60%).
Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for minimal clearance.
Category D/X
Category C
Corticosteroid
Corticosteroid